Skip to content

Evaluating Serum Sestrin in Leiomyoma Patients

Evaluation of Serum Sestrin Levels in Patients With Leiomyoma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04819633
Enrollment
61
Registered
2021-03-29
Start date
2021-01-01
Completion date
2021-04-01
Last updated
2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Leiomyoma

Brief summary

Leiomyomas are the most common benign neoplasms of women's reproductive system affecting 20-30% of women within the reproductive ages. Sestrins are serum proteins which are highly expressed under circumstances of DNA damage, hypoxia and oxditive stress and play an important role in autophagia. The aim of this study is to evaluate the relationship of serum sestrin proteins with development of leiomyomas.

Detailed description

Leiomyomas are the benign neoplasms of uterus and the role of genetics, estrogen levels and obesity has already been shown in their development. Higher levels of serum sestrin proteins have already been associated with DNA damage, hypoxia and oxidative stress and sestrin plays an important role in autophagia. In order to evaluate the role of serum sestrin in the development of leiomyomas 30 patients between 18-45 years of age who were diagnosed with uterine leiomyomas with transvaginal ultrasonography will be included in the study group. Their serum sestrin levels will be determined and compared with that of 30 healthy subjects recruited during the same study period at the same clinic.

Interventions

OTHERDetermination of serum sestrin levels

Serum sestrin levels will be determined using venous blood samples obtained from the subjects.

Sponsors

Sisli Hamidiye Etfal Training and Research Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-45 years of age * patients diagnosed with uterine leiomyomas will be included in the study group * patients without any additional comorbidities * patients without any autoimmune diseases

Exclusion criteria

* patients with systemic diseases * patients with known chronic inflammatory diseases * patients using hormonal and/or medical therapy * pregnant women * lactating women * patients with malignant diseases

Design outcomes

Primary

MeasureTime frameDescription
Evaluating the role of autophagia in the development of leiomyomas by evaluating the serum sestrin levels.2 monthsIncreased levels of serum sestrin proteins are associated with impaired autophagia. This association will be evaluated in the context of leiomyoma patients by measuring serum sestrin levels in blood samples obtained from these patients and comparing them with the sestrin levels measured in healthy subjects.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026